Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (11603)	10/12/1999 10:40:00 AM
From: Mr.Manners	Respond to of 150070

OSTX Tuesday October 12, 7:57 am Eastern Time Company Press Release Ostex International Announces FDA Clearance for New Osteomark NTx Point-of-care Test Company Signs Exclusive U.S. Distribution Agreement With PSS World Medical, Inc. SEATTLE--(BW HealthWire)--Oct. 12, 1999--Ostex International, Inc. (Nasdaq:OSTX - news) today announced FDA clearance for its new Osteomark® NTx Point-Of-Care device for testing in the physician's office. The Company also announced that it has signed an agreement with PSS World Medical, Inc. as its exclusive U.S. distribution partner for the NTx Point-Of-Care device. Today's announcement follows the Company's introduction earlier this year of its Osteomark NTx Serum test for centralized laboratory testing. Osteomark NTx Point-Of-Care is a disposable single-use device that permits a physician to measure a patient's NTx level as an indicator of bone resorption while the patient is in the physician's office. Knowing a patient's NTx level is a valuable tool used in the management and prevention of osteoporosis. The Ostex easy-to-use, disposable NTx Point-Of-Care device is the first and only to provide a quantitative measurement of the NTx bone resorption marker in a point-of-care format. Thomas Bologna, chairman, president, and chief executive officer, stated, ''FDA clearance of the Osteomark NTx Point-Of-Care device is a significant event for Ostex, and the doctors and patients we serve. NTx Point-Of-Care enables physicians to obtain an NTx level in just five minutes. This new means for measuring NTx will make testing for how well antiresorptive drugs such as Merck's Fosamax®, Lilly's Evista® and American Home's Premarin® are working to decrease bone resorption easier and faster than ever. Instead of sending samples to the laboratory, physicians using the NTx Point-Of-Care device can obtain immediate results that can be used in making decisions about treatment while the patient is still in their office. We believe this new one of a kind format will help to significantly broaden the market opportunity for the NTx test.'' Bologna continued, ''We are pleased to have PSS World Medical, Inc. as our exclusive U.S. distributor for the NTx Point-Of-Care device for the physician's office. As the leading distributor of medical products to the physician's office, PSS has an unparalleled reputation for excellence. The company has over 700 sales representatives calling directly on physicians' practices in all 50 states. With the introduction of the NTx Point-Of-Care device and our exclusive U.S. distributor, we have a huge sales force that will sell the Osteomark NTx test, a strength that we never had before.'' Osteomark NTx provides a quantitative measure of cross-linked N-telopeptides of Type I collagen (NTx) as an indicator of human bone collagen breakdown. Knowing a patient's NTx level is valuable information for monitoring bone resorption changes in three months versus 1 to 2 years with bone mineral density measurement. PSS World Medical, Inc. is the market leader in serving physicians. Recently PSS was recognized in the H.R. Chally Physician Office World Class Study ranking by customers as the best national company for customer satisfaction. Sales & Marketing Management magazine ranked PSS as 5th best for all industries. Additional information on PSS World Medical, Inc. can be obtained by accessing its homepage at pssd.com. Ostex International is engaged in the discovery and commercialization of products associated with osteoporosis and other collagen-related diseases. The Company's lead product, the Osteomark NTx test, now available in multiple test formats, incorporates breakthrough and patented technology for the management and prevention of osteoporosis. The Company is in the later stages of development of a patented cartilage breakdown test that is designed to determine if an individual is at risk for osteoarthritis and, if so, determine if treatment for the disease is working. Forward looking statements in this release involve a number of risks and uncertainties including, but not limited to, product demand, pricing, market acceptance of the Osteomark test, changing economic conditions, the actions of competitors, the effect of the Company's accounting polices, meeting regulatory and CLIA waiver requirements for the Company's new product, and other risk factors detailed in the Company's SEC filings. Contact: Ostex International, Inc Thomas A. Bologna, 206/292-8082 (Company Contact) tbologna@ostex.com OR Investor Relations Cassie R. Vlk, 206/292-8082 (Financial Contact) cvlk@ostex.com OR Fax On Demand 800/356-8061 OR businesswire.com More Quotes and News: Ostex International Inc (NasdaqNM:OSTX - news) Related News Categories: biotech, medical/pharmaceutical